Nicholas Piramal to focus on mega brands
18 Jun 2002
![](http://www.domain-b.com/companies/companies_n/nicholas_piramal/nicholas_logo.gif)
The company plans to gradually phase out its tertiary brands that account for 9 per cent of its turnover.
The company will aggressively launch new products belonging to the high-growth therapeutic segments, which include oral anti-diabetics, anti-depressants, cardiovascular and anti-arthritic drugs. In the previous fiscal, drugs in the respiratory, cardiac, NSAIDs and psychiatry segment accounted for 42 per cent of the company’s formulation turnover.
As a consequence of its integration with Rhone-Poulenc India Ltd, the company has significantly reduced operational complexity of its plants. It has consolidated in-house manufacturing locations in order to align capacities with future demand requirements.